TSHA Stock Forecast & Price Target

Taysha Gene Therapies is viewed positively because TSHA-102 has shown compelling Rett syndrome efficacy, with an 83% response rate at six months rising to 100% at 12 months in 12 initial patients, alongside 310 total functional gains and 31 developmental milestones. These results sit well above the FDA-aligned 33% threshold, suggest broad benefit across communication, motor skills, sleep, and seizures, and are reinforced by continued improvement with longer follow-up and excellent safety. The outlook is further supported by a strong probability of success in the pivotal REVEAL readout in 1H27, while the company remains a single-segment, clinical-stage gene therapy business focused on a high-need indication with no approved disease-modifying therapy.

Taysha Gene Therapies is viewed negatively because its lead programs still face meaningful clinical and regulatory uncertainty despite encouraging efficacy signals, and the dataset remains small relative to the burden of proving durable, differentiated benefit. Safety concerns are a key overhang, including the prior higher-dose NGN-401 systemic hyperinflammatory syndrome/HLH-like immune toxicity and the second sensory neuropathy case that raises the possibility of dorsal root ganglion toxicity, even as Taysha reported no treatment-related SAEs or DLTs across N=29 for TSHA-102 and N=35 at the current NGN-401 dose. Financially, the company is likely to require additional equity financing to advance development and build commercialization capabilities, creating dilution risk in a capital-intensive, highly competitive gene therapy market.